Trial Profile
A Double Blind, Dose-Ranging, Phase 1 Study In Healthy Volunteers to Assess Safety and the Phosphate Binding Capacity of Lanthanum Dioxycarbonate (SPI-014, Renazorb)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 May 2014
Price :
$35
*
At a glance
- Drugs Lanthanum carbonate (Primary)
- Indications Hyperphosphataemia
- Focus Therapeutic Use
- Sponsors Spectrum Pharmaceuticals
- 27 May 2014 New trial record